| Proposed Ticker: CPCP | 200 Cascade Boulevard | |
| Exchange: NASDAQ-National Market | Milford, Connecticut 06460 | |
| Industry: Manufacturing | (203) 877-1999 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 5/23/96 | |
| U.S. Shares Filed: | 2,000,000 | Filing Range: | $9.00 - $11.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $20,000,000 | |
| Primary Shares: | 2,000,000 | Expenses: | $700,000 | |
| Secondary Shares: | 0 | Shs Out After: | 5,892,166 | |
| Manager | Tier | Phone |
| Advest, Inc. | Lead Manager | (203) 525-1421 |
| Cruttenden & Company, Inc. | Co-manager | (714) 757-5700 |
| Cruttenden Roth Incorporated | Co-manager | (800) 678-9147 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $1.08 |
| Net Income: | -$2.33 | -$0.90 | -$0.42 | Liabilities: | $9.39 |
| EPS: | -$0.56 | -$0.22 | -$0.11 | Equity: | -$8.31 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company manufactures software driven ventilators for the treatment of intensive care and anesthesia patients. The Company's first product, the Venturi ventilator, incorporates proprietary "smart" software and pneumatic hardware to continuously control patient airway flow and pressure throughout all phases of the respiratory cycle, including the active control of exhalation. These unique features enable continuous automatic adjustment within and between individual breaths to tune therapy to patient-specific demands and to supplement the patients's spontaneous breathing efforts without suppressing or mechanically overriding the patient's natural drive to breathe. The Company believes that these features will fundamentally change the practice of applied respiratory care by reducing the work of breathing, accelerating weaning from mechanical ventilatory support and reducing ventilator dependence. As a result, the Company believes the Venturi will improve patient outcomes, shorten the length of hospital stays and reduce treatment costs. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for development of future products, production of ventilators, establishment of a marketing and sales force and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.